Safety and tolerability of high-intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus
| Autor: | Ian B. Hollis, Morgan E. Corkish, Shelby L. Tjugum, Stephanie A. Heeney |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Statin Heart Diseases Maximum Tolerated Dose medicine.drug_class Hyperlipidemias 030204 cardiovascular system & hematology 030230 surgery Gastroenterology Tacrolimus 03 medical and health sciences chemistry.chemical_compound Postoperative Complications 0302 clinical medicine Internal medicine Hyperlipidemia medicine Humans Retrospective Studies Transplantation biology Cholesterol business.industry Incidence Middle Aged Prognosis medicine.disease United States Discontinuation Rosuvastatin Calcium Tolerability chemistry HMG-CoA reductase biology.protein Heart Transplantation Drug Therapy Combination Female lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors business Immunosuppressive Agents Follow-Up Studies |
| Zdroj: | Clinical Transplantation. 33:e13454 |
| ISSN: | 0902-0063 |
| DOI: | 10.1111/ctr.13454 |
| Popis: | Background Following heart transplantation (HT), HMG CoA reductase inhibitors (statins) have been shown to reduce total and low-density lipoprotein (LDL) cholesterol, development of cardiac allograft vasculopathy (CAV), and mortality. Studies in HT patients have demonstrated the safety of low/moderate intensity statins; however, little data exist using high-intensity (HI) statins. The study aim was to evaluate the safety and efficacy of HI statins in HT recipients receiving tacrolimus. Methods This single-center, retrospective analysis included adult HT recipients from January 1, 2005, to December 31, 2015, who received HI statin therapy during posttransplant follow-up. The primary outcome, tolerability, was defined as the absence of myalgias, hepatotoxicity, rhabdomyolysis, or HI statin dose reduction/discontinuation. The secondary end point was the mean reduction in total and LDL cholesterol. Results Among the 24 patients included, one experienced myalgias and therapy discontinuation (4%; P > 0.99). No other HI statin dose reduction/discontinuation occurred, and no instances of rhabdomyolysis or hepatotoxicity were observed. The average reduction in total and LDL cholesterol after conversion to HI statin was 35 mg/dL (P = 0.02) and 19 mg/dL (P = 0.10), respectively. Conclusions High-intensity statin therapy appears safe and efficacious in HT recipients receiving tacrolimus and is a reasonable option for the treatment of refractory hyperlipidemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text